Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PTPRC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PTPRC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTPRC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTPRC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTPRC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123314 | Breast | IDC | regulation of apoptotic signaling pathway | 82/1434 | 356/18723 | 6.27e-20 | 5.93e-17 | 82 |
GO:200123514 | Breast | IDC | positive regulation of apoptotic signaling pathway | 31/1434 | 126/18723 | 4.13e-09 | 3.35e-07 | 31 |
GO:009719114 | Breast | IDC | extrinsic apoptotic signaling pathway | 42/1434 | 219/18723 | 2.56e-08 | 1.73e-06 | 42 |
GO:200123614 | Breast | IDC | regulation of extrinsic apoptotic signaling pathway | 32/1434 | 151/18723 | 1.07e-07 | 6.26e-06 | 32 |
GO:004578514 | Breast | IDC | positive regulation of cell adhesion | 62/1434 | 437/18723 | 1.70e-06 | 7.16e-05 | 62 |
GO:005165114 | Breast | IDC | maintenance of location in cell | 37/1434 | 214/18723 | 2.39e-06 | 9.35e-05 | 37 |
GO:001033211 | Breast | IDC | response to gamma radiation | 16/1434 | 56/18723 | 2.84e-06 | 1.08e-04 | 16 |
GO:001021213 | Breast | IDC | response to ionizing radiation | 28/1434 | 148/18723 | 6.85e-06 | 2.09e-04 | 28 |
GO:000931412 | Breast | IDC | response to radiation | 62/1434 | 456/18723 | 6.91e-06 | 2.10e-04 | 62 |
GO:005123513 | Breast | IDC | maintenance of location | 48/1434 | 327/18723 | 9.90e-06 | 2.77e-04 | 48 |
GO:004211012 | Breast | IDC | T cell activation | 64/1434 | 487/18723 | 1.49e-05 | 3.77e-04 | 64 |
GO:005086311 | Breast | IDC | regulation of T cell activation | 47/1434 | 329/18723 | 2.49e-05 | 5.91e-04 | 47 |
GO:000181911 | Breast | IDC | positive regulation of cytokine production | 61/1434 | 467/18723 | 2.81e-05 | 6.58e-04 | 61 |
GO:005087011 | Breast | IDC | positive regulation of T cell activation | 34/1434 | 216/18723 | 4.59e-05 | 1.03e-03 | 34 |
GO:007149614 | Breast | IDC | cellular response to external stimulus | 45/1434 | 320/18723 | 5.40e-05 | 1.15e-03 | 45 |
GO:005134814 | Breast | IDC | negative regulation of transferase activity | 39/1434 | 268/18723 | 7.89e-05 | 1.56e-03 | 39 |
GO:190370612 | Breast | IDC | regulation of hemopoiesis | 49/1434 | 367/18723 | 9.74e-05 | 1.86e-03 | 49 |
GO:000715912 | Breast | IDC | leukocyte cell-cell adhesion | 49/1434 | 371/18723 | 1.27e-04 | 2.33e-03 | 49 |
GO:003530414 | Breast | IDC | regulation of protein dephosphorylation | 18/1434 | 90/18723 | 1.39e-04 | 2.48e-03 | 18 |
GO:000268311 | Breast | IDC | negative regulation of immune system process | 55/1434 | 434/18723 | 1.53e-04 | 2.67e-03 | 55 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTPRC | SNV | Missense_Mutation | | c.794N>A | p.Cys265Tyr | p.C265Y | | protein_coding | tolerated(0.08) | possibly_damaging(0.9) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.2299N>T | p.Pro767Ser | p.P767S | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.448N>A | p.Gly150Arg | p.G150R | | protein_coding | tolerated(0.11) | possibly_damaging(0.486) | TCGA-AC-A2FM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTPRC | SNV | Missense_Mutation | novel | c.977A>C | p.Lys326Thr | p.K326T | | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | novel | c.319N>T | p.Pro107Ser | p.P107S | | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.1538N>A | p.Gly513Asp | p.G513D | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTPRC | SNV | Missense_Mutation | rs758824419 | c.2695N>A | p.Glu899Lys | p.E899K | | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PTPRC | SNV | Missense_Mutation | novel | c.2476N>C | p.Glu826Gln | p.E826Q | | protein_coding | deleterious(0.01) | possibly_damaging(0.669) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PTPRC | SNV | Missense_Mutation | | c.3337N>A | p.Asp1113Asn | p.D1113N | | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PTPRC | SNV | Missense_Mutation | | c.308N>T | p.Ser103Leu | p.S103L | | protein_coding | tolerated(0.73) | benign(0.084) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | [131I]-BC8 | | |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | HYDROGEN PEROXIDE | HYDROGEN PEROXIDE | 15012988 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | PREDNISONE | PREDNISONE | 17063711 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | ERYTHROPOIETIN | EPOETIN BETA | 1713254 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | GM-CSF/IL-3 FUSION PROTEIN | | 1713254 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | etanercept | ETANERCEPT | 20309874,23007924 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | VACCINE | | 12007880 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | adalimumab | ADALIMUMAB | 20309874,23007924 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | PROTEIN KINASE INHIBITOR | | 9473774 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | LM-CD45 | | |